# Association between kidney measurements and

#### cognitive performance in patients with ischemic stroke 2

3	Running title: Kidney measures and Cognitive Function
4	
5	Author name: Chunyan Zhang¹, Guofang Xue¹, Yanjuan Hou², Pengfei Meng¹,
6	Huizhong Gao¹, Bo Bai¹, Dongfang Li¹
7	
8	<sup>1</sup> Author affiliations: Department of Neurology, Second Hospital, Shanxi Medical
9	University, 382 Wuyi Road, Taiyuan, Shanxi, China;
10	<sup>2</sup> Author affiliations: Department of Nephrology, Second Hospital, Shanxi Medical
11	University, 382 Wuyi Road, Taiyuan, Shanxi, China.
12	*Correspondence: Chunyan Zhang
13	Address: Second Hospital, Shanxi Medical University, 382 Wuyi Road, Taiyuan, Shanxi,
14	China;
15	Email: marzipanzcy@126.com
16	
17	
18	
19	

# **Abstract**

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

**Background** Relationships between low estimated glomerular filtration rate (eGFR) and albuminuria with poorer cognitive performance in patients with ischemic stroke are less clear. Our aim was to retrospectively ascertain the associations between these renal measures and cognitive performance in patients with ischemic stroke. **Methods** Retrospective analysis was performed on 608 patients with acute ischemic stroke. Urine albumin-creatinine ratio (UACR) and eGFR were obtained from inpatient medical records. Global cognitive function via mini-mental state exam (MMSE) and Montreal Cognitive Assessment (MoCA) was determined one month after hospital discharge. The relationship between renal measures and cognitive performance was assessed using univariate and multiple linear regression analyses. **Results** Patients had an average age of 66.6±4.1 years, and 48% were females. Average eGFR and UACR were 88.4±12.9 ml/min/1.73m<sup>2</sup> and 83.6±314.2 mg/g, respectively. The number of patients with an eGFR of ≥90, 60 to 89, and <60 ml/min/1.73 m<sup>2</sup> were (371, 61%), (207, 34%) and (30, 5%) respectively. The proportions with a UACR <30 mg/g, 30-300mg/g and >300 mg/g were 56%, 39% and 5%. Multivariate adjusted models showed that eGFR was independently associated with MMSE ( $\beta$ = -0.4; 95% CI= -0.5,-0.4; p <0.001) and MoCA ( $\beta$  = -0.6; 95% CI= -0.7,-0.5; p <0.001). However, the correlations between UACR and MMSE and MoCA were

statistically non-significant. **Conclusion** In patients with ischemic stroke, reduced eGFR but not albuminuria was associated with lower cognitive performance. These results show that the eGFR decline could be an effective indicator of cognitive impairment after a stroke. Therefore, regular monitoring and early detection of mild renal dysfunction in patients with acute ischemic stroke might be needed. Keywords: cognitive performance, elderly, estimated glomerular filtration rate, urine albumin-to-creatinine ratio, ischemic stroke

# Introduction

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Globally, cognitive impairment is a major health problem during old age. Due to better living conditions and healthcare, humans have extended lifespans, and this has led to a rapid increase in the prevalence of cognitive dysfunction disorders.(1) The identification of modifiable risk factors of cognitive decline or dementia is of vital importance in developing preventive strategies.(2) Chronic kidney disease (CKD) is a global health burden with a high economic cost to health systems. CKD is defined by indicators of renal dysfunction, such as estimated glomerular filtration rate (eGFR), and kidney damage, such as urine albumin-creatinine ratio (UACR).(3) Numerous cross-sectional or longitudinal studies have been performed to explore the relationship between kidney disease and cognitive dysfunction, but the available data are conflicting.(4-15) A recent study on the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) revealed that decreased eGFR had a significant association with an increased risk of cognitive dysfunction in a cohort of older adults. (16) The Maastricht Study found albuminuria but not eGFR to be independently associated with cognitive impairment, specifically within the domain of information processing speed. However, both albuminuria and eGFR were more significantly associated with cognitive impairment in older individuals.(6) A prospective study in a Chinese

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

population aged 80 years and more found early-stage CKD to have a correlation with cognitive decline.(17) Palmer et al found that in the African-American population with type 2 diabetes (T2D), eGFR and albuminuria were associated with cognitive dysfunction, even in mild kidney disease. (18) Cognitive impairment was found to occur early in CKD.(19) However, Helmer et al did not find an increased risk of cognitive decline or dementia to be associated with low eGFR level. Rather, they found that a faster decline in eGFR and proteinuria was associated with incidence of cognitive impairment and dementia with a vascular component. (20) The incidence of cognitive impairment after cerebrovascular accidents (CVA) in China is as high as 80.9%, including 48.91% for cognitive impairment without dementia and 32.05% for cognitive impairment with dementia. (21) Patients with CVA are at a high risk of suffering cognitive dysfunction. CVA increased the relative risk of dementia by 3.7-fold to 6.6-fold in older adults aged 61-74 years, and advanced the onset of dementia by nearly 10 years. (22) However, few studies have examined whether the association between low eGFR and albuminuria with poorer cognitive performance are limited to individuals with high-risk factors or patients with stroke. A longitudinal study found that CKD was independently related to incident dementia in patients with vascular risk factors and partly support a role for common vascular mechanisms

as the underlying pathophysiology of AD dementia. (23) Recently, a study in patients

with TIA and stroke found CKD was not independently associated with either pre- or post-event dementia, suggesting that renal-specific mechanisms are unlikely to play an important role in aetiology.(24)

This study aimed to investigate whether low eGFR and albuminuria, measured by UACR, are independently and/or jointly associated with worse cognitive performance in patients with ischemic stroke.

# **Materials and Methods**

#### **Data source**

Using a retrospective design, this study analyzed data from 608 patients aged 60 to 80 years with acute ischemic stroke within 72 hours of onset between January 2016 and December 2020 from inpatient medical records and a database of cognitive assessment results for outpatient visits one month after hospital discharge. Data was collected from September 1, 2019. During or after data collection, investigators had access to information that could identify individual patients. All patients were no history of a cognitive disorder before stroke and were able to complete the assessment, excluding patients who could not cooperate with the examination, such as aphasia or consciousness disorder. The study was conducted at the Department of Neurology, Second Hospital of Shanxi Medical University, Taiyuan, a tertiary hospital

in Shanxi, China. This study was approved by the Ethics Committee of the Second Hospital of Shanxi Medical University (NO. 2019YX214). The research was completed in accordance with Helsinki Declaration. Due to the retrospective nature of the study, informed consent of the patients was not required. The data included renal function parameters, such as serum creatinine and UACR, and cognitive function test findings, such as mini-mental status examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores.

#### Clinical and laboratory data

Clinical data extracted from hospital records on admission, included systolic and diastolic blood pressure on admission, self-reported demographic characteristics (age, gender, height, weight, years of education, smoking and alcohol consumption status, and diabetes mellitus and hypertension history), laboratory results (total cholesterol, triglyceride, homocysteine, uric acid, fasting glucose, urea, creatinine, and UACR). Additionally, data on neural function assessment (National Institutes of Health Stroke Scale [NIHSS] score) were available. All patients were diagnosed as large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO), stroke of other determined cause (SOC), and stroke of undetermined cause (SUC) according to TOAST classification.(25) Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. eGFR was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, which is more accurate than the modification of diet in renal disease (MDRD) equation.(26)

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

eGFR=141×min(Scr/k,1) $\alpha$ ×max(Scr/k,1) $\alpha$ -1.209×0.993 $\alpha$ e×1.018[if female] Where serum creatinine (Scr) is expressed in mg/dL and age in years;  $\kappa$  is 0.7 for females and 0.9 for males;  $\alpha$  is -0.329 for females and -0.411 for males; min indicates the minimum of Scr/ $\kappa$  or 1, and max indicates the maximum of Scr/ $\kappa$  or 1. Cognitive impairment testing All the cognitive function tests were assessed by two neuropsychological assessors trained in consistency using MMSE and MoCA one month after hospital discharge. The MMSE and MoCA scores ranged from 0 to 30; higher scores indicated better cognitive function. MMSE testing components included 30 point within four dimensions: ten points for orientation, six for registration and memory, five for attention and calculation, and nine for language and visuospatial abilities. MoCA testing domains included visuospatial and executive function (5 points), naming (3 points), memory (5 points), attention (6 points), language/abstraction (5 points) and orientation (6 points). **Statistical analysis** The study was based on analysis of data obtained from a retrospective design. Patient characteristics were presented as means ± standard deviations (SD) for continuous variables, and categorical variables were reported as frequencies and percentages. Differences between groups for continuous data were tested by one-

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

way analysis of variance (ANOVA). Differences between groups for proportions were tested with a Chi-square test. Data on UACR were not normally distributed; therefore, they were log-transformed before analysis. Standard definitions were used to categorize eGFR data into three groups, comprising ≥90 ml/min/1.73 m<sup>2</sup> as reference, 60–89 ml/min/1.73 m<sup>2</sup>, and <60 ml/min/1.73 m<sup>2</sup>. Thereafter, eGFR was analyzed as a continuous variable (per 5 mL/min/1.73 m<sup>2</sup> decreased). UACR values were categorized as <30 mg albumin/g creatinine (normal to mildly increased as reference), 30–300 mg/g (moderately increased), and >300 mg/g (severely increased). Multivariate linear regression was used to assess the association between eGFR or UACR and cognitive performance, with eGFR or UACR as the independent variable and MoCA and MMSE scores as the dependent variables. Two models, Models 1 and 2, were used for the regression analysis. Model 1 was crude, and multivariate-adjusted Model 2 was constructed to adjust for potential confounding variables associated with kidney function and/or cognitive function, including age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure (SBP), and either eGFR or UACR. Crude and adjusted ß with 95% CIs are presented. Two-tailed P < 0.05 was considered statistically significant. All analyses

were performed using Empower (R)(<u>www.empowerstats.com, X&Y</u> Solutions Inc., Boston, MA) and R (<u>http://www.R-project.org</u>).

# **Results**

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

# **Population characteristics**

Table 1 shows demographic and laboratory data on all 608 patients. Patients had a mean age of 66.6 years (SD: 4.1 years) and 48% of patients were females. Average eGFR and UACR were  $88.4\pm12.9$  ml/min/1.73 m<sup>2</sup> and  $83.6\pm314.2$  mg/g, respectively. Levels of eGFR were >90 ml/min/1.73m<sup>2</sup> (N=371, 61%), 60-89 ml/min/1.73m<sup>2</sup> (N=207, 34%), and <60 ml/min/1.73m<sup>2</sup> (N=30, 5%). The number of patients with UACR<30 mg/g was 338 (56%). Moderately increased UACR, defined as a UACR 30-300mg/g, was present in 240(39%) of patients, and severely increased UACR, defined as a UACR >300 mg/g, was present in 30(5%) of patients. Patients with lower eGFR categories were more likely to be older and former or current alcohol consumers and smokers. In addition, they were more likely to have diabetes mellitus, and hypertensive disease, and high systolic blood pressure (SBP) and diastolic blood pressure (DBP) on admission. Their homocysteine, blood glucose, uric acid, and total cholesterol levels were more likely to be higher, as well as a higher BMI. The eGFR levels were lower in patients with albuminuria than in normal

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

patients. As compared with patients with UACR <30 mg/g, patients with UACR ≥30 mg/g were more likely to be living with obesity, diabetes mellitus, and hypertensive disease. Additionally, they were more likely to have higher SBP and DBP, blood glucose, uric acid, and homocysteine levels. Patients had lower cognitive scores in the lower eGFR and higher UACR categories (Table 1). Independent and combined associations between eGFR and **UACR** levels and cognitive performance Table 2 contains the results of unadjusted and fully adjusted (age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, SBP, and eGFR or UACR) models for continuous and categorical relationships between measures of renal disease and cognitive tests. The correlation between UACR and MMSE and MoCA scores in crude and multivariate adjustment were statistically non-significant. In the crude and adjusted analyses, no independent associations were observed between UACR, as a category, and cognitive performance. Similarly, no independent associations were observed when UACR was analyzed as a continuous variable in Models 1 and 2 (Table 2). The association between eGFR and the tests of cognitive performance was evaluated with crude and multivariable linear regression analyses. eGFR was analyzed as a

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

categorical ( $\geq$ 90, 60-90, and <60 ml/min/1.73 m<sup>2</sup>) and a continuous (per 5 ml/min/1.73 m<sup>2</sup> decrease) variable. In the multivariable adjustment model, for patients with eGFR 60-90 ml/min/1.73 m<sup>2</sup> compared to patients with eGFR ≥90 ml/min/1.73 m<sup>2</sup>, an association existed between eGFR and MMSE (ß,-0.7; 95%CI, -1.0 to -0.3) and MoCA (ß,-1.4; 95%Cl, -1.7 to -1.0). The association between eGFR <60 ml/min/1.73 m<sup>2</sup> and cognitive performance was stronger. In the multivariable adjustment model, MMSE and MoCA were (ß,-4.2; 95%CI -5.0,-3.4) and (ß,-5.2; 95%CI -6.1,-4.4), respectively. When examined as a continuous variable (per 5 ml/min/1.73 m<sup>2</sup> decrease) in crude and fully adjusted models, eGFR decrements were positively associated with lower MMSE and MoCA scores (p<0.001) (Table 2). In all cases, lower levels of eGFR were associated with poorer cognitive performance. To assess generalizability, a fully adjusted regression model was created for analyzing the subgroups of sex, stroke subtypes, age, SBP, NIHSS, and blood glucose levels. The results were similar in the subgroup analyses. No significant interactions were found among any of the stratified variables (male versus female, large artery versus small vessel occlusion, age, SBP, NIHSS, and blood glucose dichotomized group: higher versus lower) with eGFR or UACR for cognitive testing. (Tables 3 and 4) When combined categories of eGFR (<90 and ≥90 ml/min/1.73 m<sup>2</sup>) and albuminuria (<30 and ≥30mg/g) were analyzed, the MMSE and MoCA scores were the least in

those patients with UACR  $\geq$ 30 mg/g and eGFR <90 ml/min/1.73 m², compared to those without albuminuria and eGFR level of  $\geq$ 90 ml/min/1.73 m² in the crude and fully adjusted model (Table 5).

#### **Discussion**

This study found that in old adults with ischemic stroke in China, reduced eGFR, but not albuminuria measured by UACR, has an independent association with poorer cognitive performance. This study supports findings from prior studies reporting a link between kidney function and cognitive impairment.

## eGFR and cognitive performance

Our results showed that, in the absence or presence of albuminuria, an eGFR <90 ml/min/1.73 m² had an association with worse cognitive performance. However, the presence of albuminuria amplified the relationship. These findings corroborate the findings of prior studies on the association between renal measures and poorer cognitive performance. According to previous reports, this association exists during the early stages of renal dysfunction.(17, 18) The association between renal function and cognitive performance has been paid much attention in recent decades. Wang et al found that both CKD and eGFR were associated with cognitive dysfunction among older patients with hypertension in China.(27) A prospective study

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

demonstrated that kidney dysfunction is associated with a cognitive decline in a community-based population, and this association is independent of albuminuria.(28) Another longitudinal study suggested that a low eGFR was associated with increased risk of dementia. In addition, a faster decrease in eGFR and proteinuria was associated with incidence of cognitive impairment and dementia; this association may be mediated by vascular mechanisms.(20) Additionally, a large population study found that each 10 ml/min/1.73 m<sup>2</sup> decrease in eGFR<60 ml/min/1.73 m<sup>2</sup> was independently associated with an increased prevalence of cognitive impairment. (29) The OSACA2 study found that CKD was independently related to incident dementia in patients with vascular risk factors. (23) However, one cochort study from the Oxford Vascular Study (OXVASC) did not find CKD was associated with either pre- or postevent dementia in patients with TIA and stroke.(24) The inconsistent results may be attributable to different study populations and severity of lesion. OXVASC has focused on the relationship between CKD and dementia in the patients with TIA and stroke. Participants in SPRINT were in older community-dwelling adults with cardiovascular disease. OSACA2 was in highrisk patients for the primary and secondary prevention of cardiovascular disease. Another potential reason is different methods of assessment. Many previous studies have used different assessment tools to evaluate cognitive function.

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

Although the precise pathophysiologic mechanisms that underlie the association between low eGFR and poorer cognitive performance are not known and need further studies for clarity, several factors may help explain the association between low eGFR and cognitive dysfunction. Patients with renal dysfunction have a higher prevalence of cerebrovascular disease (CVD) than the general population. Renal dysfunction may contribute to vascular cognitive impairment through traditional CVD risk factors, including hypertension, diabetes mellitus, dyslipidemia, smoking, and other non-traditional vascular risk factors comprising hyperhomocysteinemia, hyperuricemia, anemia, inflammation, and oxidative stress. Moreover, CKD characterized by the accumulation of uremic toxins, excessive RAS activation, renal anemia, and renal osteopathy, caused by renal dysfunction are possible mechanisms of renal disease involvement in the progression of dementia. (30, 31) Conceptually, low eGFR may lead to the accumulation of neurotoxins or may represent a prolonged exposure to CVD or its risk factors.(6) Vascular dementia is often linked to hypertension, which is a common finding in CKD. Hypertension has often been associated with small lacunar infarcts and leukoaraiosis, cerebral autoregulation dysfunction, and chronic hypoperfusion. Although cerebral blood flow may be adequate in CKD, the blood-brain barrier or the glymphatic system might be dysfunctional. In this study, more than 50% of the patients had hypertension. Uremic toxins in circulation, which enter the central nervous system (CNS) as a result of blood-brain barrier damage during kidney dysfunction, might impair CNS structure and function.(32)

## Albuminuria and cognitive performance

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

According to recent systematic review and meta-analysis studies, albuminuria has a significant association with cognitive impairment and dementia. (4, 33, 34) To the best of our knowledge, albuminuria is a significant risk factor for the development of dementia in community-based Japanese older adults. Moreover, low eGFR and albuminuria are mutually associated with a greater risk of vascular dementia. (35) A prospective cohort study demonstrated that persistent or progressive albuminuria is associated with cognitive decline in adults with diabetes and normal eGFR. (36) Wei et al found that urine albumin is significantly associated with cognitive dysfunction, and can be potentially used as an early marker for CKD.(37) The mechanism underlying the association between albuminuria and poorer cognition is not completely understood and is likely multifactorial. Both cerebral and renal circulations have high flow and low impedance. The association between albuminuria and cognitive impairment probably reflects common microvascular pathogenesis in the kidneys and brain. Several reasons may explain the inconsistencies between our findings and those of previous reports. First, the

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

conflicting results may be attributable to use of different study populations in studying the severity of albuminuria. Patients with cognitive dysfunction may reflect in another chronic microvascular disease. This may explain why dementia and poorer cognitive performance are more common in individuals with diabetes who have a high prevalence of albuminuria.(36, 38) However, since fewer patients with diabetes participated in this study (8%), these findings should be interpreted with caution. The study might be underpowered to detect the association between UACR and poorer cognitive performance. Second, this study only measured UACR at a single time point. UACR is affected by exercise and the time of day the sample is taken, (39) which is why repeated measurements would be preferred. The true association between albuminuria and cognitive performance is likely to be diluted. An alternative explanation for the disparate results of the association between low eGFR and albuminuria and poorer cognitive performance could be that albuminuria is a marker for a different condition other than kidney disease.(40) This study had several strengths. First, the primary independent and dependent variables were quantified using clinically relevant measures (eGFR and UACR for two independent markers of renal function and damage and MoCA and MMSE for cognitive performance), thus providing clinical relevance to the analyses. In addition, the use of both eGFR and UACR as correlators enabled us to test their independent

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

and joint effects on cognitive performance. Second, the study controlled for several potential confounders, including demographic and clinical parameters, while assessing the association. Several limitations were noted. First, our study population contained a small number of partients with CKD (eGFR <60 ml/min/1.73 m<sup>2</sup>), which limited our ability to detect a relationship between eGFR <60 ml/min/1.73 m<sup>2</sup> and cognitive performance. Second, these parameters were based on a one-time evaluation and do not provide information on the duration or severity of risk factors over time. Third, we did not analyze impairment in specific cognitive domains; instead, overall cognitive scores were used in the analysis. Finally, the cognitive assessment was performed one month after hospital discharge, and the incidence of post-stroke cognitive impairment is highest three months after stroke.(41) Further long-term follow-up is still needed. Our findings support the hypothesis that renal dysfunction and albuminuria may operate through different pathophysiologic mechanisms. They further suggest that the pathways mediating the association between low eGFR and albuminuria and poorer cognitive performance may be partially distinct. The findings have clinical implications. Our results suggest that the measurement of eGFR is a good biomarker for cognitive impairment in patients with acute ischemic stroke. Low eGFR may

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

reflect a partially distinct pathophysiologic process of cognitive dysfunction. Targeting the pathogenesis of low eGFR or treating modifiable risk factors may have clinical implications in preventing cognitive impairment or delaying disease progression. Further studies are needed to confirm whether the setting of kidney dysfunction is a possible new determinant for cognitive impairment in patients with stroke. **Conclusion** Our findings suggest that in patients with ischemic stroke, reduced eGFR but not albuminuria was associated with cognitive impairment, measured by MMSE or MoCA. The eGFR decline could be an effective indicator of cognitive impairment after a stroke. These results suggest that the early stages of renal dysfunction could be an effective target to prevent cognitive impairment in patients with stroke. It emphasizes the need and possibility for early detection and early cognitive impairment prevention after stroke. **Acknowledgments** None.

# References

365

- 366 Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global
- 367 prevalence of dementia: a systematic review and metaanalysis. Alzheimer's &
- 368 dementia: the journal of the Alzheimer's Association. 2013 Jan;9(1):63-75.e2.
- 369 PubMed PMID: 23305823. Epub 2013/01/12. eng.
- Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S. Systematic 370
- 371 review: factors associated with risk for and possible prevention of cognitive decline in
- 372 later life. Annals of internal medicine. 2010 Aug 3;153(3):182-93. PubMed PMID:
- 373 20547887. Epub 2010/06/16. eng.
- 374 Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al.
- 375 Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-
- 376 Analysis. PloS one. 2016;11(7):e0158765. PubMed PMID: 27383068. Pubmed Central PMCID: Pmc4934905. Epub 2016/07/08. enq. 377
- 378 Deckers K, Camerino I, van Boxtel MP, Verhey FR, Irving K, Brayne C, et al. 4.
- 379 Dementia risk in renal dysfunction: A systematic review and meta-analysis of
- 380 prospective studies. Neurology. 2017 Jan 10;88(2):198-208. PubMed PMID:
- 381 27974647. Pubmed Central PMCID: Pmc5224710. Epub 2016/12/16. eng.
- 382 Weiner DE, Gaussoin SA, Nord J, Auchus AP, Chelune GJ, Chonchol M, et al.
- 383 Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood
- 384 Pressure Intervention Trial (SPRINT). American journal of kidney diseases: the
- 385 official journal of the National Kidney Foundation, 2017 Sep;70(3):357-67, PubMed
- 386 PMID: 28606731. Pubmed Central PMCID: Pmc5572661. Epub 2017/06/14. eng.
- 387 Martens RJ, Kooman JP, Stehouwer CD, Dagnelie PC, van der Kallen CJ,
- 388 Koster A, et al. Estimated GFR, Albuminuria, and Cognitive Performance:
- 389 The Maastricht Study. American journal of kidney diseases: the official journal of the
- 390 National Kidney Foundation. 2017 Feb;69(2):179-91. PubMed PMID: 27291486. Epub 391
- 2016/06/14. eng.
- 392 Ekblad LL, Toppala S, Johansson JK, Koskinen S, Sundvall J, Rinne JO, et al.
- 393 Albuminuria and Microalbuminuria as Predictors of Cognitive Performance
- 394 in a General Population: An 11-Year Follow-Up Study. Journal of Alzheimer's disease:
- 395 JAD. 2018;62(2):635-48. PubMed PMID: 29480195. Epub 2018/02/27. eng.
- 396 Kong JY, Kim JS, Kang MH, Hwang HS, Won CW, Jeong KH. Renal
- 397 dysfunction is associated with decline of cognitive function in community-dwelling
- 398 older adults: Korean frailty and aging cohort study. 2020 Nov 10;20(1):462. PubMed 399 PMID: 33172388.
- 400 Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and 9.
- 401 cognitive impairment: a systematic review and meta-analysis. American journal of
- 402 nephrology. 2012;35(5):474-82. PubMed PMID: 22555151. Epub 2012/05/05. eng.
- Kurella Tamura M, Yaffe K, Hsu CY, Yang J, Sozio S, Fischer M, et al. 403
- 404 Cognitive Impairment and Progression of CKD. American journal of kidney diseases:
- 405 the official journal of the National Kidney Foundation. 2016 Jul;68(1):77-83. PubMed
- 406 PMID: 26972681. Pubmed Central PMCID: Pmc4921255. Epub 2016/03/15. eng.
- 407 Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJ, et al.
- 408 Association of cognitive function with albuminuria and eGFR in the general
- 409 population. Clinical journal of the American Society of Nephrology: CJASN. 2011
- 410 Jun;6(6):1400-9. PubMed PMID: 21566108. Pubmed Central PMCID: Pmc3109938.
- 411 Epub 2011/05/14. eng.
- Barzilay JI, Younes N, Pop-Busui R, Florez H, Seaguist E, Falck-Ytter C, et al. 412 12.
- 413 The cross-sectional association of renal dysfunction with tests of cognition in middle-
- 414 aged adults with early type 2 diabetes: The GRADE Study. Journal of diabetes and its

- 415 complications. 2021 Mar;35(3):107805. PubMed PMID: 33288412. Pubmed Central
- 416 PMCID: Pmc7870547. Epub 2020/12/09. eng.
- 417 13. Feng L, Yap KB, Yeoh LY, Ng TP. Kidney function and cognitive and functional
- decline in elderly adults: findings from the Singapore longitudinal aging study.
- Journal of the American Geriatrics Society. 2012 Jul;60(7):1208-14. PubMed PMID:
- 420 22702744. Epub 2012/06/19. eng.
- 421 14. Kono S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, et al.
- 422 Impact of cystatin C and microalbuminuria on cognitive impairment in the population
- of community-dwelling Japanese. Atherosclerosis. 2017 Oct;265:71-7. PubMed PMID:
- 424 28865325. Epub 2017/09/03. eng.
- 425 15. Lee S, Shimada H, Park H, Makizako H, Lee S, Doi T, et al. The association
- 426 between kidney function and cognitive decline in community-dwelling, elderly
- Japanese people. Journal of the American Medical Directors Association. 2015
- 428 Apr;16(4):349.e1-5. PubMed PMID: 25669668. Epub 2015/02/12. eng.
- 429 16. Paterson EN, Maxwell AP, Kee F, Cruise S, Young IS, McGuinness B, et al.
- 430 Association of renal impairment with cognitive dysfunction in the Northern Ireland
- 431 Cohort for the Longitudinal Study of Ageing (NICOLA). 2021 Jul 23;36(8):1492-9.
- 432 PubMed PMID: 34038557.
- 433 17. Bai K, Pan Y, Lu F, Zhao Y, Wang J, Zhang L. Kidney function and cognitive
- decline in an oldest-old Chinese population. Clinical interventions in aging.
- 435 2017;12:1049-54. PubMed PMID: 28740370. Pubmed Central PMCID: Pmc5505158.
- 436 Epub 2017/07/26. eng.
- 437 18. Palmer ND, Sink KM, Smith SC, Xu J, Bowden DW, Hugenschmidt CE, et al.
- 438 Kidney disease and cognitive function: African American-diabetes heart study MIND.
- 439 American journal of nephrology. 2014;40(3):200-7. PubMed PMID: 25323981.
- 440 Pubmed Central PMCID: Pmc4216628. Epub 2014/10/18. eng.
- 441 19. Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, et al. Cognition in
- 442 chronic kidney disease: a systematic review and meta-analysis. BMC medicine. 2016
- 443 Dec 14;14(1):206. PubMed PMID: 27964726. Pubmed Central PMCID: Pmc5155375.
- 444 Epub 2016/12/15. eng.
- 445 20. Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, et al.
- 446 Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study.
- 447 Neurology. 2011 Dec 6;77(23):2043-51. PubMed PMID: 22116945. Epub 2011/11/26.
- 448 eng.
- 449 21. Qu Y, Zhuo L, Li N, Hu Y, Chen W, Zhou Y, et al. Prevalence of post-stroke
- 450 cognitive impairment in china: a community-based, cross-sectional study. PloS one.
- 451 2015;10(4):e0122864. PubMed PMID: 25874998. Pubmed Central PMCID:
- 452 Pmc4395303. Epub 2015/04/16. eng.
- 453 22. De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi D, Ferrari B, et al. The
- 454 combined effect of age, education, and stroke on dementia and cognitive impairment
- 455 no dementia in the elderly. Dementia and geriatric cognitive disorders.
- 456 2007;24(4):266-73. PubMed PMID: 17700023. Epub 2007/08/19. eng.
- 457 23. Miwa K, Tanaka M, Okazaki S, Furukado S, Yagita Y, Sakaguchi M, et al.
- 458 Chronic kidney disease is associated with dementia independent of cerebral small-
- 459 vessel disease. Neurology. 2014 Mar 25;82(12):1051-7. PubMed PMID: 24553427.
- 460 Epub 2014/02/21. eng.
- 461 24. Kelly DM, Pendlebury ST. Associations of Chronic Kidney Disease With
- Dementia Before and After TIA and Stroke: Population-Based Cohort Study. 2022
- 463 Feb 15;98(7):e711-e20. PubMed PMID: 34996878.
- 464 25. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al.
- 465 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter

- 466 clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993
- 467 Jan;24(1):35-41. PubMed PMID: 7678184. Epub 1993/01/01. eng.
- 468 26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et
- al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May
- 470 5;150(9):604-12. PubMed PMID: 19414839. Pubmed Central PMCID: Pmc2763564.
- 471 Epub 2009/05/06. eng.
- 472 27. Wang H, Liu T, Cai YY, Jiang H, Liu HX, Lin C. Kidney Function and Cognitive
- 473 Impairment in People Aged 80 Years and Over with Untreated Hypertension: A
- 474 Cross-Sectional Survey. Kidney & blood pressure research. 2016;41(1):70-7. PubMed
- 475 PMID: 26872346. Epub 2016/02/13. eng.
- 476 28. Wang F, Zhang L, Liu L, Wang H. Level of kidney function correlates with
- cognitive decline. American journal of nephrology. 2010;32(2):117-21. PubMed PMID:
- 478 20714128. Epub 2010/08/18. eng.
- 479 29. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al.
- 480 Kidney function and cognitive impairment in US adults: the Reasons for Geographic
- and Racial Differences in Stroke (REGARDS) Study. American journal of kidney
- diseases: the official journal of the National Kidney Foundation. 2008
- 483 Aug;52(2):227-34. PubMed PMID: 18585836. Pubmed Central PMCID: Pmc2593146.
- 484 Epub 2008/07/01. eng.
- 485 30. Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, et al.
- 486 Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic
- 487 Renal Insufficiency Cohort (CRIC) study. Clinical journal of the American Society of
- 488 Nephrology: CJASN. 2011 Feb;6(2):248-56. PubMed PMID: 20930087. Pubmed
- 489 Central PMCID: Pmc3052213. Epub 2010/10/12. eng.
- 490 31. Zhang J, Tang L, Hu J, Wang Y, Xu Y. Uric acid is associated with cognitive
- impairment in the elderly patients receiving maintenance hemodialysis-A two-center
- 492 study. 2020 Mar;10(3):e01542. PubMed PMID: 31985179.
- 493 32. Viggiano D, Wagner CA, Martino G. Mechanisms of cognitive dysfunction in
- 494 CKD. 2020 Aug;16(8):452-69. PubMed PMID: 32235904.
- 495 33. Georgakis MK, Dimitriou NG, Karalexi MA, Mihas C, Nasothimiou EG,
- 496 Tousoulis D, et al. Albuminuria in Association with Cognitive Function and Dementia:
- 497 A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society.
- 498 2017 Jun;65(6):1190-8. PubMed PMID: 28152169. Epub 2017/02/06. eng.
- 499 34. Li H, Zhao S, Wang R, Gao B. The association between cognitive
- 500 impairment/dementia and albuminuria: a systematic review and meta-analysis.

501 Clinical and experimental nephrology, 2021 Aug 28, PubMed PMID: 34468878, Epub

- 502 2021/09/02. eng.
- 503 35. Takae K, Hata J, Ohara T, Yoshida D, Shibata M, Mukai N, et al. Albuminuria
- 504 Increases the Risks for Both Alzheimer Disease and Vascular Dementia in
- 505 Community-Dwelling Japanese Elderly: The Hisayama Study. Journal of the American
- Heart Association. 2018 Jan 20;7(2). PubMed PMID: 29353232. Pubmed Central
- 507 PMCID: Pmc5850144. Epub 2018/01/22. eng.
- 508 36. Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, et al.
- Albuminuria and cognitive decline in people with diabetes and normal renal function.
- 510 Clinical journal of the American Society of Nephrology: CJASN. 2013
- 511 Nov;8(11):1907-14. PubMed PMID: 23990163. Pubmed Central PMCID: Pmc3817915.
- 512 Epub 2013/08/31. eng.
- 513 37. Wei YK, Zhu J. Early markers of kidney dysfunction and cognitive
- impairment among older adults. Journal of the neurological sciences. 2017 Apr
- 515 15;375:209-14. PubMed PMID: 28320132. Epub 2017/03/23. eng.
- 516 38. Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, et al.
- 517 Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.

518 Archives of internal medicine. 2011 Jan 24;171(2):142-50. PubMed PMID: 21263104. 519 Epub 2011/01/26. eng.

- 520 39. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, et al.
- 521 Current issues in measurement and reporting of urinary albumin excretion. Clinical
- 522 chemistry. 2009 Jan;55(1):24-38. PubMed PMID: 19028824. Epub 2008/11/26. eng.
- 523 40. Fried L. Albuminuria and cognitive impairment. Clinical journal of the
- 524 American Society of Nephrology: CJASN. 2012 Mar;7(3):376-8. PubMed PMID:
- 525 22282483. Epub 2012/01/28. eng.
- 526 41. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology,
- mechanisms and management. Annals of translational medicine. 2014 Aug;2(8):80.
- 528 PubMed PMID: 25333055. Pubmed Central PMCID: Pmc4200648. Epub 2014/10/22.
- 529 eng.

530

531

532

Table 1 Demographic and clinical characteristics of patients stratified by eGFR and UACR

	Overall		imated glomeru ion(ml/min/1.7			Urinary ACR (mg/g)			
	O VOIMII	≥90	60-89	<60	P	<30	30-300	>300	P
	$92.9 \pm 12.2$ $355 (58.5)$ $64 (10.5)$ $188 (31.0)$ $389 (64.0)$ $52 (8.6)$	n=371	n=207	n=30	value	n=338	n=240	n=30	value
Age, y	$66.6 \pm 4.1$	$65.5 \pm 3.5$	$68.0 \pm 4.5$	$69.8 \pm 4.5$	< 0.001	$66.4 \pm 4.2$	$66.8 \pm 4.1$	$66.3 \pm 3.7$	0.45
Male, n(%)	316 (52.0)	192 (51.8)	105 (50.7)	19 (63.3)	0.43	186 (55.0)	115 (47.9)	15 (50.0)	0.235
$BMI$ , a $kg/m^2$	$25.0 \pm 3.6$	$24.8 \pm 3.4$	$24.9 \pm 3.8$	$26.6 \pm 4.0$	0.033	$24.6 \pm 3.4$	$25.3 \pm 3.7$	$25.9 \pm 3.8$	0.019
Education (> 6 years),n (%)	200 (32.9)	130 (35.0)	58 (28.0)	12 (40.0)	0.158	113 (33.4)	77 (32.1)	10 (33.3)	0.943
Systolic blood pressure on admission, mmHg	$171.9 \pm 20.2$	$170.0 \pm 19.8$	$174.2 \pm 20.7$	$178.9 \pm 19.4$	0.008	170.3 ± 18.4	$173.8 \pm 22.1$	$174.8 \pm 23.3$	0.079
Diastolic blood pressure on admission, mmHg	$92.9 \pm 12.2$	$92.1 \pm 12.1$	$93.9 \pm 12.4$	$96.5 \pm 12.7$	0.057	91.5 ± 11.7	94.6 ± 12.7	95.5 ± 12.8	0.006
Smoking, n (%)					0.112				0.057
Never	355 (58.5)	229 (61.7)	114 (55.3)	12 (40.0)		182 (54.0)	153 (63.7)	20 (66.7)	
Former	64 (10.5)	33 (8.9)	26 (12.6)	5 (16.7)		34 (10.1)	26 (10.8)	4 (13.3)	
Current	188 (31.0)	109 (29.4)	66 (32.0)	13 (43.3)		121 (35.9)	61 (25.4)	6 (20.0)	
Alcohol drinking, n (%)					0.474				0.18
Never	389 (64.0)	245 (66.0)	128 (61.8)	16 (53.3)		205 (60.7)	163 (67.9)	21 (70.0)	
Former	52 (8.6)	27 (7.3)	21 (10.1)	4 (13.3)		33 (9.8)	15 (6.2)	4 (13.3)	
Current	167 (27.5)	99 (26.7)	58 (28.0)	10 (33.3)		100 (29.6)	62 (25.8)	5 (16.7)	

Diabetes mellitus, <sup>b</sup> n (%)	50 (8.2)	34 (9.2)	13 (6.3)	3 (10.0)	0.45	21 (6.2)	23 (9.6)	6 (20.0)	0.019
Hypertension, n (%)	361 (59.4)	215 (58.0)	127 (61.4)	19 (63.3)	0.656	189 (55.9)	154 (64.2)	18 (60.0)	0.138
Stroke subtypes					0.149				0.911
Large artery	281 (46.2)	183 (49.3)	80 (38.6)	18 (60.0)		156 (46.2)	110 (45.8)	15 (50.0)	
Small vessel occlusion	309 (50.8)	176 (47.4)	121 (58.5)	12 (40.0)		171 (50.6)	124 (51.7)	14 (46.7)	
Cardioembolism	13 (2.1)	9 (2.4)	4 (1.9)	0 (0.0)		8 (2.4)	4 (1.7)	1 (3.3)	
Other determined etiology	3 (0.5)	1 (0.3)	2 (1.0)	0 (0.0)		1 (0.3)	2 (0.8)	0 (0.0)	
Undetermined etiology	2 (0.3)	2 (0.5)	0 (0.0)	0 (0.0)		2 (0.6)	0 (0.0)	0 (0.0)	
Laboratory results									
Total cholesterol, mmol/L	$5.7 \pm 1.2$	$5.6 \pm 1.1$	$5.8 \pm 1.3$	$5.8 \pm 1.3$	0.055	$5.7 \pm 1.2$	$5.7 \pm 1.2$	$6.0 \pm 1.1$	0.423
Triglyceride, mmol/L	$1.6 \pm 0.9$	$1.7 \pm 1.1$	$1.5 \pm 0.7$	$1.6 \pm 0.7$	0.036	$1.5\pm0.8$	$1.8 \pm 1.1$	$1.6 \pm 0.5$	0.016
Homocysteine, umol/L	$16.1 \pm 9.4$	$14.7 \pm 7.9$	$17.0 \pm 8.6$	$27.9 \pm 18.7$	< 0.001	$15.5 \pm 7.1$	17.0 ± 11.7	17.1 ± 10.2	0.124
Uric Acid, mmol/L	$298.6 \pm 75.4$	$284.5 \pm 68.9$	$312.3 \pm 75.2$	377.7 ± 89.6	< 0.001	299.0 ± 71.8	296.2 ± 79.5	313.0 ± 81.9	0.511
Fasting glucose, mmol/L	$6.1 \pm 1.8$	$6.2 \pm 2.0$	$6.1 \pm 1.6$	$6.3 \pm 1.4$	0.698	$6.0 \pm 1.7$	$6.2 \pm 1.9$	$6.7\pm2.5$	0.082
Estimated glomerular filtration rate,mL/min/1.73m <sup>2</sup>	$88.4 \pm 12.9$	$96.0 \pm 5.3$	$79.8 \pm 8.5$	$53.2 \pm 8.2$	< 0.001	89.0 ± 11.9	$88.3 \pm 13.0$	$81.8 \pm 19.8$	0.013
Log10 Urinary ACR	$1.5\pm0.5$	$1.5 \pm 0.5$	$1.5\pm0.4$	$1.7\pm0.7$	0.246	$1.2\pm0.2$	$1.8\pm0.3$	$2.8\pm0.3$	< 0.001
Neural function assessment, mean (SD)									
MMSE score, mean $\pm$ SD (range 0–30)	$21.4 \pm 2.1$	$22.0 \pm 1.9$	$21.1 \pm 1.6$	$17.5 \pm 2.8$	< 0.001	$21.5 \pm 2.0$	$21.4 \pm 2.1$	$20.8 \pm 2.9$	0.18

MoCA score, mean $\pm$ SD (range 0–30)	$17.9 \pm 2.3$	$18.7 \pm 2.0$	$17.2 \pm 1.9$	$13.4 \pm 2.6$	< 0.001	$18.0 \pm 2.3$	$17.9 \pm 2.3$	$17.2 \pm 2.8$	0.18
NIHSS score, mean $\pm$ SD (range 0–24)	$5.0 \pm 2.2$	$5.1 \pm 2.3$	$4.8 \pm 2.1$	$5.6 \pm 1.8$	0.091	$5.1 \pm 2.2$	$4.8 \pm 2.1$	$5.3 \pm 2.8$	0.302

Abbreviations: BMI, body mass index. UACR: urine albumin-creatinine ratio

Values are presented as mean  $\pm$  SD for continuous variables and n (%) for categorical variables.

<sup>&</sup>lt;sup>a</sup> BMI was calculated as weight in kilograms divided by height in meters squared.

<sup>&</sup>lt;sup>b</sup>Diabetes mellitus was defined as self-reported physician diagnosed diabetes.

<sup>&</sup>lt;sup>C</sup>Hypertension was defined as self-reported physician diagnosed hypertension.

Table 2 Linear regression analysis of the association between levels of eGFR and albuminuria measured by UACR and cognitive performance

	NI C		MN	MSE	MoCA					
Variables	No. of patients (%)	Crude		adjusted*	k	Crude		adjusted*	k	
	•	β (95%CI)	$\overline{P}$	β (95%CI)	$\overline{P}$	ß (95%CI)	P	ß (95%CI)	P	
eGFR, (ml/min/categories	/1.73m <sup>2</sup> )									
≥90	371(61)	0		0		0		0		
60-90	207(34)	-0.9 (-1.2, -0.6)	< 0.001	-0.7 (-1.0, -0.3)	< 0.001	-1.5 (-1.8, -1.2)	< 0.001	-1.4 (-1.7, -1.0)	< 0.001	
<60	30(5)	-4.4 (-5.1, -3.8)	< 0.001	-4.2 (-5.0, -3.4)	< 0.001	-5.3 (-6.0, -4.5)	< 0.001	-5.2 (-6.1, -4.4)	< 0.001	
eGFR per 5- unit decline	608(100)	-0.4 (-0.5, -0.4)	< 0.001	-0.4 (-0.5, -0.4)	< 0.001	-0.5 (-0.6, -0.5)	< 0.001	-0.6 (-0.7, -0.5)	< 0.001	
UACR(mg/g) c	•									
<30	338(56)	0		0		0		0		
30-300	240(39)	-0.1 (-0.4, 0.3)	0.716	0.0 (-0.3, 0.3)	0.971	-0.0 (-0.4, 0.3)	0.858	0.0 (-0.3, 0.3)	0.826	
≥300	30(5)	-0.7 (-1.5, 0.0)	0.064	-0.3 (-1.0, 0.4)	0.387	-0.8 (-1.7, 0.0)	0.065	-0.2 (-0.9, 0.6)	0.68	
log-UACR	608(100)	-0.2 (-0.6, 0.2)	0.262	-0.0 (-0.4, 0.3)	0.784	-0.3 (-0.6, 0.1)	0.214	-0.0 (-0.4, 0.3)	0.834	

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

<sup>\*</sup>Adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either baseline estimated glomerular filtration rate or UACR.

Table 3 Multivariable adjusted\* Linear regression of MMSE scores with UACR and eGFR within subgroups

	Comparing UACR (30-300, >300 vs <30mg/g)			P for	Com	P for		
Subgroups	<30	30-300	>300	interaction	≥90	60-90	<60	interaction
		β (	95%CI) P			В	(95%CI) P	
Gender				0.050				0.123
Male	0	0.3 (-0.1, 0.7) 0.137	-0.5 (-1.5, 0.4) 0.278		0	-1.0 (-1.5, -0.5) < 0.001	-4.1 (-5.2, -3.1) < 0.001	
Female	0	-0.4 (-0.8, 0.1) 0.104	-0.2 (-1.2, 0.8) 0.703		0	-0.5 (-1.0, -0.0) 0.050	-4.4 (-5.7, -3.1) < 0.001	
Age dichotome	ous			0.588				0.609
Lower	0	-0.0 (-0.5, 0.4) 0.842	-0.7 (-1.7, 0.4) 0.215		0	-0.8 (-1.3, -0.3) 0.002	-5.8 (-7.4, -4.3) < 0.001	
Higher	0	0.1 (-0.4, 0.5) 0.717	0.3 (-0.7, 1.3) 0.503		0	-0.8 (-1.2, -0.4) < 0.001	-3.9 (-4.6, -3.1) < 0.001	
Systolic blood pressure dichotomous				0.657				0.149
Lower	0	-0.1 (-0.5, 0.4) 0.781	-0.2 (-1.3, 0.9) 0.740		0	-0.6 (-1.2, -0.1) 0.021	-2.8 (-4.2, -1.4) < 0.001	
Higher	0	0.1 (-0.3, 0.5) 0.652	-0.3 (-1.2, 0.7) 0.562		0	-0.7 (-1.2, -0.2) 0.005	-4.2 (-5.1, -3.3) < 0.001	
NIHSS score of	lichoton	nous		0.375				0.953
Lower	0	-0.2 (-0.7, 0.3) 0.393	-0.6 (-1.7, 0.5) 0.304		0	-0.6 (-1.1, -0.0) 0.035	-3.7 (-5.4, -2.0) < 0.001	
Higher	0	0.1 (-0.3, 0.5) 0.767	-0.0 (-0.9, 0.9) 0.982		0	-0.7 (-1.1, -0.2) 0.006	-4.2 (-5.1, -3.3) < 0.001	
Stroke subtypes				0.311				0.122
Large artery	0	0.1 (-0.4, 0.6) 0.661	0.3 (-0.7, 1.3) 0.531		0	-0.8 (-1.4, -0.2) 0.006	-4.3 (-5.3, -3.2) < 0.001	
Small vessel occlusion	0	-0.2 (-0.6, 0.2) 0.330	-0.4 (-1.4, 0.6) 0.441		0	-0.5 (-1.0, -0.1) 0.026	-4.0 (-5.3, -2.8) < 0.001	
Blood glucose	dichoto	mous		0.849				0.372
Lower	0	-0.3 (-0.9, 0.2) 0.225	-2.5 (-5.2, 0.1) 0.059		0	-1.0 (-1.5, -0.5) < 0.001	-4.5 (-5.7, -3.4) < 0.001	

Higher 0 0.1 (-0.4, 0.6) 0.768 -0.0 (-1.4, 1.3) 0.951  $_{0}$  -0.5 (-1.0, 0.0) 0.065 -3.9 (-5.1, -2.8) < 0.001

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

<sup>\*</sup>Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

Table 4 Multivariable adjusted\* Linear regression of MoCA scores with UACR and eGFR within subgroups

	Co	omparing UACR (30-300	, >300 vs <30mg/g)	P for	Com	P for		
	<30	30-300	>300	interaction	≥90	60-90	<60	interaction
Subgroups		В	(95%CI) P			В	(95%CI) P	
Gender				0.107				0.195
Male	0	0.3 (-0.1, 0.8) 0.149	-0.1 (-1.1, 1.0) 0.910		0	-1.7 (-2.2, -1.1) < 0.001	-5.4 (-6.5, -4.3) < 0.001	
Female	0	-0.3 (-0.8, 0.2) 0.197	-0.2 (-1.3, 0.8) 0.673		0	-1.1 (-1.7, -0.6) < 0.001	-4.8 (-6.2, -3.3) < 0.001	
Age dichotome	ous			0.352				0.341
Lower	0	0.1 (-0.4, 0.6) 0.658	-0.6 (-1.7, 0.6) 0.345		0	-1.3 (-1.9, -0.7) < 0.001	-6.1 (-8.0, -4.3) < 0.001	
Higher	0	0.1 (-0.4, 0.5) 0.819	0.4 (-0.6, 1.4) 0.411		0	-1.4 (-1.9, -0.9) < 0.001	-5.1 (-6.1, -4.1) < 0.001	
Systolic blood	pressu	re dichotomous		0.595				0.402
Lower	0	0.0 (-0.5, 0.5) 0.922	0.1 (-1.0, 1.3) 0.825		0	-1.2 (-1.8, -0.7) < 0.001	-4.2 (-5.6, -2.7) < 0.001	
Higher	0	0.0 (-0.4, 0.4) 0.969	-0.3 (-1.3, 0.7) 0.533		0	-1.4 (-1.9, -0.9) < 0.001	-5.7 (-6.8, -4.6) < 0.001	
NIHSS score of	lichoto	mous		0.422				0.835
Lower	0	-0.3 (-0.8, 0.3) 0.318	-0.1 (-1.2, 1.1) 0.932		0	-1.3 (-1.9, -0.7) < 0.001	-5.1 (-7.0, -3.3) < 0.001	
Higher	0	-0.1 (-1.2, 1.1) 0.932	-0.1 (-1.0, 0.9) 0.879		0	-1.4 (-1.9, -0.9) < 0.001	-5.3 (-6.3, -4.4) < 0.001	
Stroke subtype	es			0.391				0.576
Large artery	0	0.3 (-0.2, 0.7) 0.277	0.2 (-0.8, 1.3) 0.653		0	-1.4 (-2.0, -0.8) < 0.001	-4.9 (-6.0, -3.8) < 0.001	
Small vessel occlusion	0	-0.2 (-0.7, 0.2) 0.310	0.1 (-1.0, 1.2) 0.825		0	-1.3 (-1.8, -0.8) < 0.001	-5.7 (-7.1, -4.2) < 0.001	
Blood glucose	dichote	omous		0.409				0.585
Lower	0	0.0 (-0.4, 0.5) 0.960	-0.5 (-1.5, 0.5) 0.303		0	-1.7 (-2.3, -1.1) < 0.001	-5.3 (-6.6, -4.0) < 0.001	
Higher	0	-0.0 (-0.5, 0.4) 0.838	-0.1 (-1.1, 1.0) 0.918		0	-1.1 (-1.7, -0.6) < 0.001	-5.1 (-6.3, -3.9) < 0.001	

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

Table 5 Association of joint UACR and eGFR stratum with cognitive performance (β 95% CI)

		MN	MSE	MoCA  UACR(mg/g) categories		
eGFR, (ml/min/1.73m <sup>2</sup> )		UACR(mg/	g) categories			
		<30	≥30	<30	≥30	
≥90	Crude	0.00	0.0 (-0.4, 0.4)	0.00	0.2 (-0.3, 0.6)	
	Adjusted*	0.00	-0.0 (-0.4, 0.4)	0.00	0.1 (-0.3, 0.6)	
<90	Crude	-1.2 (-1.7, -0.8)	-1.5 (-2.0, -1.0)	-1.7 (-2.2, -1.3)	-2.1 (-2.6, -1.6)	
	Adjusted*	-0.8 (-1.3, -0.4)	-1.0 (-1.5, -0.5)	-1.4 (-1.9, -0.9)	-1.7 (-2.3, -1.2)	

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR, urine albumin-creatinine ratio.

<sup>\*</sup>Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

<sup>\*</sup> adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure.